Bayer
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.
Business & Industry
- Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
- Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
- COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials
- Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
- BioNTech and Pfizer initiate rolling submission to European Medicines Agency for SARS-CoV-2 vaccine candidate BNT162b2
Research & Development
- A vaccine project funded by the Federal Ministry for Economic Affairs and Energy develops a second generation COVID-19 vaccine
- NIH begins large clinical trial to test immune modulators for treatment of COVID-19
- Scientists identify common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses
- Popular COVID-19 conspiracies linked to vaccine 'hesitancy'
- World Bank approves $12 billion for COVID-19 vaccines
- Can an antibody 'cocktail' prevent COVID-19 infection?
- Total deaths recorded during the pandemic far exceed those attributed to COVID-19
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults
- EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation
- FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
- FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials